Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)

Next Previous
Trial Profile

Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary) ; Finerenone (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CONFIRMATION-HF

Most Recent Events

  • 23 Jul 2026 Planned End Date changed from 1 Aug 2026 to 1 Nov 2027.
  • 23 Jul 2026 Planned primary completion date changed from 1 Jul 2026 to 1 Nov 2027.
  • 11 Mar 2025 Planned End Date changed from 1 Aug 2025 to 1 Aug 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top